

Innovation... Growth,... Success... Experienced Each Day








Innovation...Growth...Success... ...Experienced Each Day


Our mission.....to become a Research based International Pharmaceutical Company has been our driving force over the years. Market leadership is synonymous with customer orientation, **innovation** and strategic agility. We continue to drive our markets forward by consistently keeping pace with cutting edge technology creating significant value and intellectual property.

Ranbaxy is ranked amongst the Top 100 global pharmaceutical companies...In 2001 our US subsidiaries earned the distinction of achieving the fastest growth in the world's largest pharmaceutical market. It attained sales of over US\$ 100 million within four years of its operations.

Innovation in all facets of research continued to strengthen our presence in the domestic and international markets with a specific focus on technology intensive - difficult to make niche products. The **success** is evident with all our overseas subsidiaries delivering profits this year. With the US\$ 1 billion mark within striking distance, we are now envisioning the new growth horizon, as we progress towards our cherished mission.....










- 1. Davinder S. Brar, CEO & Managing Director
- 2. Dr. Brian W. Tempest, President, Pharmaceuticals
- 3. Dr. J. M. Khanna, President, R&D
- 4. Vinay Kaul, Executive Vice President, Finance & Corporate Services
- 5. Bimal K. Raizada, Sr. Vice President
- 6. Udai Upendra, Vice President, Global Human Resources
- 7. Pushpinder Bindra, Sr. Vice President, Global Manufacturing
- 8. Sanjiv D. Kaul, Regional Director, India
- 9. Peter Burema, Regional Director, Europe, CIS & Africa
- 10. Vinod Dhawan, Regional Director, Asia Pacific, Latin America & Canada www.reportjunction.com



www.reportjunction.com

- 11. Dipak Chattaraj, President, Ranbaxy Pharmaceuticals Inc.
- 12. Atul Malhotra, Head, Global OTC Business & Regional Director, Middle East
- 13. Rahul Goswami, Vice President, Strategic Planning & CIO
- 14. Rajiv Malik, Vice President, Pharma Research and Regulatory Affairs
- 15. K. Srinivas, Vice President, API Business & Centralised Purchasing
- 16. Malvinder M. Singh, Director, Global Licensing & Business Development
- 17. Lalit Ahluwalia, Director, Business Finance
- 18. Dr. Arun Purchit, Director, Global Marketing
- 19. Ameet Desal, Director, Mergers & Acquisitions

WILESTONES

1007 YAAUUA

- mentsiv ni viilise7 Permission received to set up a Manufacturing
- First to receive **approvals to launch Caverta** in India, its Sildenafil brand
- FICCI Award presented to Ranbaxy by India's PM, recognising corporate initiatives in Science and Fechnology in 2000

W∀BCH 2001

- US\$ 5 Min received from Bayer for successful completion of Phase I Trials of the Cipro drug Ranbaxy USA, awarded Rite Aid 2000 (USA's Ranbaxy USA, awarded Rite Aid 2000 (USA's
- 3rd-largest retail pharmacy chain) Supplier of the
- Ohm Laboratories Inc. received US FDA Vear Award
- approval to market Ibuprofen and Pseudoephedrine Hydrochloride tablets USP

∀PRIL 2001

- Ranbaxy launched Anti-HDS medicines to enter
- A unique once-a-day formulation, Offoxacin (Anti-bacterial fluroquinolone), was developed by Radnaxy; an IND is to be filed in the US shortly sibnl ni Jnamgaz sirl

1007 PNOI

develop a novel, cost-effective, patent-protected, oral-controlled release system Ranbaxy collaborated with Vectura Limited, UK, to

IULY 2001

- for its Anti-AIDS drug, Lamivudine trinontuA violaluses final set mon the subsection of the set of th Ranbaxy S.P. Medicamentos, Brazil, received
- RPI receives **US FDA approval** to market Cephalexin for Oral Suspension **USP**
- ASU ni ynegmoo gniworg-leetest IMS June 2001 report declared Ranbaxy as the

Products sold in over 100 countries; Manufacturing facilities in 7 countries; 019

Rs. 10,000 Mn, against the ambitious target of Rs. 10,000 Mn, during the year

during the year Ranbary ranked No: 7 amongst the Top 10 companies in India in an annual survey conducted by Far Eastern Economic Review, Asia's leading

belit č.t. terringia, ASU ni bevieden zlavongga AGNA 5

RPI received US FDA approval for Acetaminophen and Codeine Phosphate tablets USP
Ranbaxy Nigena Ltd. signed an agreement worth Ranbaxy Nigena Ltd. signed an agreement worth Lamivudine, Stavudine and Nevitapine – to the Federal Ministry of Health, Nigeria

Renbaxy to co-market Ranbaxy's Ciprofloxacin-OD

thiw task a ngie seinsqmoa amtad gnibsel a'sibni

Ranbaxy **Iaunched** two NDDS products in India – Citran OD, once-a-day Ciprofloxacin and Sanocin OD, once-a-day Ofloxacin

its unique once-a-day formulation, Ciprofloxacin RPI receives US FDA approval for Lorazepam tablets USP

Ranbaxy received approval, from the Drugs Controller General of India (DCGI), for launching

, nM E11 & SU of behnuoms sels? another 2U

of betruoms stroots sibnl-x3 s'yxednes

business weekly

%#7 to thworg 6

DECEMBER 2001

NOAEWBEB 5001

OCLOBER 2001

SEPTEMBER 2001

¥007 T2001

Series

JANUARY 2001

- i da de

MARCH 2001

- on bet from drug Ard 2000 (US Anti Stoppies o
 - ectived US FDA splen and schlor de rables HSP

APRIL 2001

JUNE 2001

Train and the

JULY 2001

u**h**ydda**ll**a

AUGUST 2001

SEPTEMBER 2001

OCTOBER 2001

NOVEMBER 2001

erdéniques consequencies

DECEMBER 2001





CONTENTS

01. A	64 - S. S.	288 P. 18 M.	12.18 million 44	. N. Same	Sec. 1.	19 10 100
<u>Chain</u>	nenis i	libess	<u>ce</u>			6
	an is					a Maria
0	i URA					8
	51 11					5. See 19
Bonpo	rele C	overn	ance			11
	1992 - AN		1	- 10		(1948) (1948)
Cipera	tions i	Xeview	۴.,			16
	95					
	rch &		opme		1000	18
	sal Ac	vien	1		2940 - 197	24
		Deut	*	C. y. Q.	- (23), 2) 1 - (1)	25
	erket s				The second	25
A setting	Phar	necett		marai	flonte	38
Ravie	See Street at the				acino	00
				n na series Sectores de la companya de la company		
And the second second second	and the second se		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ALC: NO PARA ALC: NO PARA	19.00 March 19.000 March 19.000	

40 roduct Review . . . **Global Manufacturing** 42 (MCA) **Allied Businesses** 44 Č. P.R. New Initiatives 46 - Global Licensing - Consumer Healthcare 1000 Sear Low Wa **Operating Subsidiaries & Affiliates - 48** Results at a Glance 16. T \$ and the second 49 **Board of Directors** 1.1 **Report of the Directors** 50 Ten Years at a Glance 59 $\{\mathcal{C}_{i}, \mathbf{\hat{f}}_{i}\}$ Auditors' Report 60 Accounts of Ranbaxy 62 132 **Consolidated Accounts** 83

1.211.01.523

Store 1

94 Accounts of Subsidiaries eren ander ander

Distant - Chair to under the Score and


- Zaleybar o da sa si dan por

www.reportiunction.com

SANSCO SERVICES - Annual Reports Library Services - www.sansco.net

CONTENTS

Chairman's Message	6
CEO & MD's Message	8
Corporate Governance	11
Operations Review	16
Research & Development	18
Financial Review	24
Key Markets Review	25
Active Pharmaceutical Ingredients	38
Review	
Product Review	40
Global Manufacturing	42
Allied Businesses	44
New Initiatives - Global Licensing - Consumer Healthcare	46
Operating Subsidiaries & Affiliates Results at a Glance	- 48
Board of Directors	49
Report of the Directors	50
Ten Years at a Glance	59
Auditors' Report	60
Accounts of Ranbaxy	62
Consolidated Accounts	83



Tejendra Khanna Chairman

"The Corporate Governance Committees of the Board, including the Committees of Management, Finance and Audit, have met regularly. Strong emphasis has been placed on the improvement of guality of sales and working capital management. Despite the sharp decrease in treasury income during the year, the overall profits of the Company based on its robust operations in pharmaceutical production and marketing have increased by nearly 40% compared to the preceding year.....In relation to the management of the Company's precious Human Resources, stringent compliance with the core ethical values of the Company, has been repeatedly underscored."

Dear Shareholders,

At the outset, I would like to take the opportunity of sharing with you an overview of the progress achieved by your Company during the Business Year ending December 31, 2001.

Since the last few years, your Company has been following a conscious policy of internationalising its operations to become a significant player on the global pharmaceutical stage. Your Company has been able to register an increase of 18% in the Rupee value of its sales in the year 2001 (Rs. 20,545 Mn against preceding year's aggregate sales of Rs.17,367 Mn). This is in contrast to the growth in the previous year (2000 over 1999) of 11.9%. Interestingly, for the first time, aggregate domestic sales. This is a clear indication of the effort to reach out more energetically to tap global market opportunities.

If we look at the consolidated operations of Ranbaxy Laboratories Limited, along with its subsidiaries and affiliates operating in a number of overseas countries, the Ranbaxy Group of Companies achieved global sales of US\$ 600 Mn in 2001 representing an increase of 18% over the preceding year (US\$ 507 Mn). Dosage form sales which embody higher value addition increased from 73% of the total sales revenue in 2000 to 76% in 2001. This is in accordance with the strategy of the Company to reduce the proportion of its revenues from the sale of Active Pharmaceutical Ingredients (API) and consciously increase the share of value-added dosage form products.

Your Company has identified 6 principal markets for focusing its marketing efforts. These are: India, USA, UK, Brazil, China and Germany. Of these, the star performer of the year was USA where dosage form sales rose from US\$ 65 Mn in 2000 to US\$ 113 Mn in 2001, representing an increase of 74%. Considering the fact that aggregate US sales stood at only US\$ 15 Mn in 1998, the quantum jump to US\$ 113 Mn in 2001 is a highly commendable achievement.

As far as India is concerned, though domestic sales grew at a slower pace (9.7% in Rupee terms), ex-India export sales rose sharply to cater to the junction.com